Cellectar Bioscience

Q2 FY2026 EarningsQ2 FY26 results slightly missed consensus on the bottom line, with a GAAP EPS of -$0.57 vs. the -$0.52 expected. Research and development expenses surged 91% YoY to $4.56M as the company initiated its Phase 3 confirmatory study for iopofosine I 131 in Waldenstrom macroglobulinemia (WM). While revenue remains at zero as expected for this pre-revenue biotech, a successful $35M upfront financing in May has extended the cash runway into Q2 2027.